Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Uterine Cervical Neoplasms

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

The population is represented by women being admitted to the Gynecology Ward who are affected by cervical cancer.

Blood chemistry tests: neutrophil;lymphocyte; monocyte; platelet counts

Venous blood sample

biopsy

Carlo Ronsini, MD

Although significant advances in screening and treatment , cervical cancer is the fifth most common female cancer in Europe. Major prognostic factors for oncological outcome are used to categorise patients at high, intermediate and low risk groups and to define the type of radical hysterectomy according "Querleu-Morrow classification". The goal of this prospective observational study is to evaluate the association between several inflammatory markers and risk groups according European guidelines in women with cervical cancer Human Papillomavirus (HPV)-associated, in order to optimize the treatment.

European guidelines have proposed a risk stratification of patients basing on oncological risk. The type of radical hysterectomy (extent of parametrial resection and type according Querleu-Morrow classification) should be based upon the presence of prognostic risk factors.Major prognostic factors for oncological outcome as tumour size, maximum stromal invasion, Lymphovascular space invasion (LVSI) are used to categorise patients at high, intermediate and low risk for treatment failure. The investigators want to identify additional parameters to better define risk profiles. Systemic inflammation indices such as neutrophil to lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte to monocyte ratio (LMR) have shown prognostic value in solid tumors and several inflammatory conditions. Therefore, the primary endpoint of the present study is to assess the role of systemic inflammatory indices and risk groups stratification in patients with early cervical cancer.

CERvical Cancer The InFlammatory Index (CERTIFIKO)

CERvical Cance The InFlammatory Index as a Predictor of risK Stratification:an Observational Study

Anatomic pathology report of cell anaplasia in the sampled tumor

Anatomic pathology report of extent to which the cancer has spread

Anatomic pathology report of tissue types of cancer

an absolute value obtained from the ratio of neutrophils to lymphocytes

an absolute value obtained from the ratio of platelets to lymphocytes

an absolute value obtained from the ratio of lymphocytes to monocytes

University of Campania "Luigi Vanvitelli"

Principal Investigator

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Immune Checkpoint Inhibitors

Immunomodulating Agents

Adjuvants, Immunologic

Lung cancer patients received immunological checkpoint inhibitors (ICIs) and any immunomodulatory drugs.

Lung cancer patients received immunological checkpoint inhibitors (ICIs).

Shih-Ming TSAI, M.D., Ph.D.

The main objective of this study is to evaluate the change of neutrophil to lymphocyte ratio (NLR) after 6-week treatment of immune checkpoint inhibitors (ICIs) with or without immunomodulatory drugs and recognize the effect of post-treatment NLR and overall survival in advanced lung cancer patients by retrospective review.

In recent years, the therapeutic strategies for lung cancer have been enriched with small molecular targeted therapy and immunotherapy. In this retrospective study, we will observe the change in NLR and explore its possible association with survival among advanced lung cancer patients receiving Immune checkpoint inhibitors (ICIs) with and without such immuno-modulator, Astragalus Polysaccharide Injection. It can be used to understand the relationship between NLR values and the survival rate of lung cancer patients after ICIs treatment. Physicians can refer to this result to give patients the suitable treatment recommendations.

Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator

Change in Neutrophil to Lymphocyte Ratio (NLR) and Survival Among Advanced Lung Cancer Patients Receiving Immune Checkpoint Inhibitors With Immunomodulator: a Retrospective Study

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
CERvical Cancer The InFlammatory Index (CERTIFIKO)	NCT05673252	Cervical Cancer	Venous blood sa... biopsy	18 Years -	University of Campania "Luigi Vanvitelli"
Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator	NCT04352335	Advanced Lung C...		20 Years -	Chung Shan Medical University
Change in NLR and Survival Among Advanced Lung Cancer Patients Receiving ICIs With Immunomodulator	NCT04352335	Advanced Lung C...		20 Years -	Chung Shan Medical University

Spots Global Cancer Trial Database for neutrophil to lymphocyte ratio (nlr)